Uptake of resveratrol and role of resveratrol-targeting protein, quinone reductase 2, in normally cultured human prostate cells.

Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors (2010) 0.93

Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells. Carcinogenesis (2012) 0.82

Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2. J Med Chem (2011) 0.78

Modulating Oxidative Stress Relieves Stress-Induced Behavioral and Cognitive Impairments in Rats. Int J Neuropsychopharmacol (2017) 0.78

Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One (2014) 0.77

Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science (1997) 10.90

Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci (2002) 1.88

Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem (2000) 1.59

Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol (2000) 1.59

Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer (2001) 1.57

Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res (2007) 1.55

Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res (1999) 1.54

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52

A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis (2001) 1.49

Flow cytometry in analysis of cell cycle and apoptosis. Semin Hematol (2001) 1.40

Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther (2006) 1.39

Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer (2002) 1.39

Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res (2003) 1.21

Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer (2003) 1.19

Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB J (2006) 1.19

NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem Pharmacol (2005) 1.19

Resveratrol and cancer: a review. Biomed Pharmacother (2002) 1.19

Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med (2001) 1.16

Melatonin in cancer management: progress and promise. Cancer Res (2006) 1.13

Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res (2005) 1.12

Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol (2002) 1.10

Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate (2007) 1.10

Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int J Cancer (1998) 1.09

Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem Biophys Res Commun (2004) 1.08

Stroma-epithelium crosstalk in prostate cancer. Asian J Androl (2008) 1.07

Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev (2005) 1.05

NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. Int J Cancer (2009) 1.03

Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate (2004) 1.03

Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res (2000) 0.99

Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate (2009) 0.96

Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid Redox Signal (2002) 0.95

Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP). BMC Complement Altern Med (2006) 0.90

Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation. Cancer Detect Prev (2004) 0.87

Anti-leukemia effect of resveratrol. Leuk Lymphoma (2002) 0.86

Effects of extracts of Coriolus versicolor (I'm-Yunity) on cell-cycle progression and expression of interleukins-1 beta,-6, and -8 in promyelocytic HL-60 leukemic cells and mitogenically stimulated and nonstimulated human lymphocytes. J Altern Complement Med (2002) 0.86

Specific processing of poly(ADP-ribose) polymerase, accompanied by activation of caspase-3 and elevation/reduction of ceramide/hydrogen peroxide levels, during induction of apoptosis in host HL-60 cells infected by the human granulocytic ehrlichiosis (HGE) agent. IUBMB Life (2000) 0.84

Benefits of resveratrol in women's health. Drugs Exp Clin Res (2001) 0.83

Atypical stromal hyperplasia of the prostate. Scand J Urol Nephrol (2008) 0.80

Melatonin as an adjuvant to therapeutic prostate cancer vaccines. J Pineal Res (2008) 0.80